Acute promyelocytic leukemia as a paradigm for targeted therapy

Martin S. Tallman*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Substantial progress has occurred in the treatment of acute promyelocytic leukemia (APL) because of improved understanding of the pathophysiology of the disease and identification of a molecular target. Novel agents such as all-trans retinoic acid (ATRA) (alone or combined with chemotherapy) and, more recently, arsenic trioxide have produced complete remission in most patients with newly diagnosed APL and/or relapsed or refractory disease, respectively. Use of these targeted therapies has resulted in evolution of the disease from one that was historically one of the most fatal subtypes of acute myeloid leukemia (AML) to one that appears curable in 70% to 80% of patients. The targeted approach to treatment of this disease can serve as a paradigm for the treatment of other leukemias.

Original languageEnglish (US)
Pages (from-to)27-32
Number of pages6
JournalSeminars in Hematology
Issue number2 SUPPL. 4
StatePublished - Apr 2004

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Acute promyelocytic leukemia as a paradigm for targeted therapy'. Together they form a unique fingerprint.

Cite this